BioHarvest Sciences Inc. (BHST) Q3 2024 Earnings Call Transcript Summary
BioHarvest Sciences Inc. (BHST) Q3 2024 Earnings Call Transcript Summary
Net losses totaled $2.7 million, or $0.16 per basic and diluted share, while adjusted EBITDA loss totaled $2 million.The following is a summary of the BioHarvest Sciences Inc. (BHST) Q3 2024 Earnings Call Transcript:
以下是BioHarvest Sciences Inc. (BHST) 2024年第三季度業績會摘錄的總結：
Financial Performance:
財務表現：
BioHarvest Sciences reported Q3 2024 revenue of $6.5 million, a 101% increase from the previous year, driven by strong VINIA sales.
Gross profit margin increased to 57%, reflecting a 1,200 basis point improvement year-over-year primarily due to increased manufacturing scale, improved yields, and cost reduction in downstream packaging.
Net losses totaled $2.7 million, or $0.16 per basic and diluted share, while adjusted EBITDA loss totaled $2 million.
BioHarvest Sciences報告2024年第三季度營業收入爲650萬，較去年增長101%，主要受益於VINIA銷售強勁。
毛利率提高至57%，同比提高1200個點子，主要得益於製造業-半導體規模的擴大、產量提升和下游-腦機包裝成本的降低。
淨虧損總計270萬，或每股基本和攤薄虧損0.16美元，調整後的息稅折舊攤銷前虧損總計200萬。
Business Progress:
業務進展：
Continued growth in the VINIA subscriber base and successful launch of VINIA SuperFood functional tea lineup. Anticipated launches include VINIA Pro chews and hydration solutions targeting active consumers.
Expansion into additional markets with regulatory efforts underway, and a significant focus on digitization to optimize production and gross margin outcomes.
Development of the CDMO business unit, focusing on contract development and manufacturing of botanically synthesized molecules.
VINIA訂閱用戶基礎持續增長，成功推出VINIA SuperFood功能性茶系列。預計推出的產品包括針對活躍消費的VINIA Pro咀嚼劑和補水解決方案。
在監管努力推進的情況下，向額外市場擴展，並重點推進數字化，以優化生產和毛利率結果。
發展CDMO業務部門，專注於植物合成分子的合同開發和製造。
Opportunities:
機會：
Expansion into the Canadian market following recent regulatory approval, with further exploration into other strategic markets.
Broadening the product portfolio in direct-to-consumer business by introducing new VINIA Inside products such as functional coffees and teas.
Entry into hydration and wellness categories, leveraging superior science and clinical trial-backed efficacy.
在最近獲得監管批准後，擴展到加拿大市場，並進一步探索其他戰略市場。
通過引入新的VINIA Inside產品，如功能性咖啡和茶，拓寬直消業務的產品組合。
進入水分補充和健康類別，利用卓越的科學和臨床試驗支持的功效。
Risks:
風險：
Challenges and delays related to the sourcing of critical raw materials for their CDMO business unit could impact project timelines and revenue recognition from these engagements.
與其CDMO業務部門關鍵原材料採購相關的挑戰和延遲可能會影響項目時間表和這些項目的營業收入確認。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
